MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ
0.4294
+0.0394
+10.10%
After Hours: 0.4270 -0.0024 -0.56% 19:22 02/06 EST
OPEN
0.3991
PREV CLOSE
0.3900
HIGH
0.4430
LOW
0.3801
VOLUME
1.20M
TURNOVER
--
52 WEEK HIGH
3.390
52 WEEK LOW
0.3801
MARKET CAP
31.56M
P/E (TTM)
-0.2394
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OTLK last week (0126-0130)?
Weekly Report · 6d ago
Outlook Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting
Reuters · 01/26 22:02
Weekly Report: what happened at OTLK last week (0119-0123)?
Weekly Report · 01/26 09:54
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Outlook Therapeutics (OTLK) and Johnson & Johnson (JNJ)
TipRanks · 01/22 08:30
Weekly Report: what happened at OTLK last week (0112-0116)?
Weekly Report · 01/19 09:58
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 01/16 21:05
Weekly Report: what happened at OTLK last week (0105-0109)?
Weekly Report · 01/12 09:57
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
NASDAQ · 01/07 14:53
More
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.

Webull offers Outlook Therapeutics Inc stock information, including NASDAQ: OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OTLK stock methods without spending real money on the virtual paper trading platform.